CIA
HUMA icon

Concurrent Investment Advisors’s Humacyte HUMA Stock Holding History

Concurrent Investment Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$25.3K – 1282
2024
Q4 		$25.3K Buy
+5,000
New +$24.7K ﹤0.01% 1086

Other funds holding HUMA

PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
LWM
LJI Wealth Management Indianapolis, Indiana $714M AUM 21.49% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CWA
Clarus Wealth Advisors Peoria, Arizona $260M AUM 27.97% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Concurrent Investment Advisors's HUMA Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Humacyte (HUMA) stake by 7.8% in Q2 2026, buying an estimated $4.63K and bringing the position to 68,979 shares worth $53.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Concurrent Investment Advisors first reported a position in HUMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $163K in Q4 2024. 43 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Concurrent Investment Advisors held 68,979 shares of Humacyte worth $53.8K as of Q2 2026.
  • Concurrent Investment Advisors bought 5,000 Humacyte shares in Q2 2026, an estimated $4.63K.
  • Humacyte made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #2063 holding.
  • Concurrent Investment Advisors first reported a position in Humacyte in Q3 2024 and has held it in 8 quarters since.
  • Concurrent Investment Advisors's Humacyte position peaked at $163K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.